Additionally, preclinical tumor models have revealed that combining HDM201 with PD-1/PD-L1 blockade can significantly increase antitumor efficacy by boosting the count of DCs and increasing the CD8 + T/Treg ratio while also elevating the concentration of IL-2 [49]. The gene discussed is CD8A; the disease is neoplasm.